

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

**(1) EFFECTIVE DATE OF THE CAPITAL REDUCTION AND
THE SUBDIVISION;
(2) REVISED TIMETABLE;
AND
(3) FREE EXCHANGE OF SHARE CERTIFICATES**

References are made to (i) the announcement of PuraPharm Corporation Limited (the “**Company**”) dated 1 November 2024; (ii) the circular of the Company dated 5 November 2024 (the “**Circular**”); and (iii) the poll results announcement of the extraordinary general meeting of the Company dated 27 November 2024 in relation to, among others, the Capital Reduction and the Subdivision. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

**EFFECTIVE DATE OF THE CAPITAL REDUCTION AND THE
SUBDIVISION**

The Board is pleased to announce that the hearing of the Company’s petition for the Capital Reduction was held on 27 January 2025 at 9:30 a.m. (Cayman Islands time) before the Court, and on 28 January 2025 (Cayman Islands time), the Court made an order confirming the Capital Reduction and such order together with the minutes approved by the Court containing the particulars required under the Companies Act with respect to the Capital Reduction were filed and duly registered with the Registrar of Companies in the Cayman Islands on 21 February 2025 (Cayman Islands time) (the “**Registration**”).

REVISED TIMETABLE AND FREE EXCHANGE OF SHARE CERTIFICATES

Upon the Registration, all the conditions precedent for the implementation of the Capital Reduction and the Subdivision have been fulfilled. Accordingly, the effective time and date for the Capital Reduction and the Subdivision shall be before 9:00 a.m. on Thursday, 13 March 2025 (Hong Kong time) and the time and date for the commencement of dealing in the New Ordinary Shares shall be revised to at 9:00 a.m. on Thursday, 13 March 2025 (Hong Kong time).

Shareholders may, during the period from 9:00 a.m. on Thursday, 13 March 2025 to 4:30 p.m. on Thursday, 24 April 2025 (both days inclusive), submit existing share certificates for the Ordinary Shares (in brown colour) to the Share Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for exchange, at the expense of the Company, for new share certificates for the New Ordinary Shares (in blue colour). All existing share certificates of the Ordinary Shares or (as the case may be) the Shares will continue to be evidence of title to such Shares but will cease to be valid for trading and settlement purpose.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 11 March 2025

As at the date of this announcement, executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.